Consun Pharmaceutical Group (HKG:1681) unit Guangzhou Consun Pharmaceutical obtained approval for a clinical trial of the SK-09 tablet from China's National Medical Products Administration, a Friday Hong Kong bourse filing said.
The indication for the approval is the treatment of podocyte injury-related renal diseases, according to the pharmaceutical firm.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.